UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 OF THE SECURITIES EXCHANGE ACT OF 1934

For the month of August 2023

Commission File Number: 001-36187

EVOGENE LTD.

(Translation of Registrant's Name into English)

13 Gad Feinstein Street, Park Rehovot, Rehovot P.O.B 4173, Ness Ziona, 7414002, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Attached hereto and incorporated by reference herein is the following exhibit:

99.1 Lavie Bio Investor Presentation.

Signature

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

EVOGENE LTD. (Registrant)

Date: August 23, 2023 By: /s/ Yaron Eldad

Yaron Eldad Chief Financial Officer

Lavie Bio

Introduction

August 2023

Forward looking statement

This presentation contains "forward-looking statements" relating to future events, and Lavie Bio (the "Company") and its parent, Evogene Ltd. ("Evogene"), may from time to time make other statements, regarding our outlook or expectations for future financial or operating results and/or other matters regarding or affecting us that are considered "forwardlooking statements" as defined in the U.S. Private Securities Litigation Reform Act of 1995 (the "PSLRA") and other securities laws, as amended. Statements that are not statements of historical fact may be deemed to be forward-looking statements.Such forward-looking statements may be identified by the use of such words as "believe", "expect", "anticipate", "should", "planned", "estimated", "intend" and "potential" or words of similar meaning. We are using forward-looking statements in this presentation when we discuss our value drivers, product pipeline, future sales, commercialization efforts and timing, product development and launches, estimated market sizes and milestones, as well as the capabilities of Evogene's and our technology.

Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this presentation. Therefore, actual future results, performance or achievements, and trends in the future may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond our control, including, without limitation, those described in greater detail in Evogene's Annual Report on Form 20-F and in other information Evogene files and furnishes with the Israel Securities Authority and the U.S. Securities and Exchange Commission, including those factors under the heading "Risk Factors".

Except as required by applicable securities laws, we disclaim any obligation or commitment to update any information contained in this presentation or to publicly release the results of any revisions to any statements that may be made to reflect future events or developments or changes in expectations, estimates, projections and assumptions.

The information contained herein does not constitute a prospectus or other offering document, nor does it constitute or form part of any invitation or offer to sell, or any solicitation of any invitation or offer to purchase or subscribe for, any securities of Evogene or the Company, nor shall the information or any part of it or the fact of its distribution form the basis of, or be relied on in connection with, any action, contract, commitment or relating thereto or to the securities of Evogene or the Company.

The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of our products or services.

Lavie Bio – In a Nutshell

Ag-Biologicals Rapidly Growing Market

The ag-biologicals market is expected to grow at a double digit CAGR

Unique AI Tech-Platform and Data Assets

Leveraging AI technology to increase:

Microbe selection predictability by 10X
Microbe efficiency by 20%

Broad & Diverse Pipeline

8 programs – new product launch expected every 1-2 years

Strategic Partners & Investors

2 Revenue Generating Graduated Programs

The Challenge

Climate Change

Unstable weather patterns
Drought & higher temperatures
Increased extreme weather

Efficiency Sustainability

Regulatory Restrictions

Limiting the use of chemicals
Enforcing regenerative practices
Regulating food imports

Pest & Disease Outbreaks

Deregulation of existing pesticides
Resistance development to chemicals
Fewer new product introductions

Consumer Demands

Healthier food
Higher quality
Sustainable production

Ag-biologicals is relatively a newcomer to the huge \$200B ag-inputs market

Chemical Fertilizers

Ag-Biologicals Could be the Solution Driving healthier crops, while preserving the soil

Consumer Health

Less residues
Less applicator exposure

Regenerative Agriculture

Improving soil fertility
Integrated pest management

Sustainability

Renewable resources
Increased uptake of fertilizers

However, Ag-Biologicals are Struggling still not efficient as 'traditional' solutions

	Chemical Crop Protection & Fertilizers	Ag-Biologicals Today
Sustainability	+	+++
Efficiency • Efficacy	+++	++
• Consistency	+++	+
• Commercial viability	+++	+

Next Generation ?

Lavie Bio – Next Generation Ag-Biologicals Efficient & Sustainable Products

	Chemical Crop Protection & Fertilizers	Ag-Biologicals Today	Ag-Biologicals
Sustainability	+	+++	+++
Efficiency • Efficacy	+++	++	+++
• Consistency	+++	+	+++
• Commercial viability	+++	+	+++

Improve food quality, sustainability and agriculture productivity through microbiome based, AI-driven, ag-biological products

Billions of microbes integral to plant-related ecosystems impact the entire plant lifecycle

Surrounding microbes generate nature's largest 'function bank' for plant growth and development

These microbes act as a 'live engine' supporting yield production in the field

The Power of the Microbiome

Billions of microbes make a difference!

Ag-Biological Product Development The ultimate case of finding "the needle in the haystack"

The challenge: finding the winning candidates out of a vast number of possible microbes that address a complex myriad of criteria, to reach successful products

Lavie Bio's Tech Edge: The Biology Driven Design (BDD) Platform

Lavie Bio's proprietary BDD platform leverages advanced computational technologies that incorporate deep scientific understanding together with big data and advanced AI, to successfully discover & guide the development of novel ag-biological products

BDD Platform - Function-Based Product Discovery Decoding the natural diversity of genetic functionality

The platform increases microbe selection predictability by 10X

BDD Platform - Function-Based Product Optimization Maximizing performance of leading microbes

End-to-End Capabilities From product concept to commercialization

Lavie Bio – Breaking the Efficiency/ Sustainability Trade-off

Case Study - Thrivus

Efficiency - Proven Capabilities

*Thrivus has regulatory approval in the US & Canada for all small grains including wheat, Barley, Durum, Oats, soybeans, canola, and others.

Data was gathered in large side-by-side field trials in the US

** In 2023 Thrivus was sold for wheat and Durum. 2023 trials for barley and oats look promising for potential 2024 expansion

Sustainability - Proven Capabilities

Bio-inoculant for cereal grains

Growers are financially rewarded for advancing sustainability

Use Thrivus bioinoculant for \$8/acre

Realize yield improvement of ± 4 bushels per acre on average from Thrivus
Enroll in the Ceres Global sustainability program

As part of the Ceres program, paid upon delivery a \$2.50/acre premium for advancing sustainability (subsidized by food companies)

Our Product Pipeline

An engine for new product launch every 1-2 years

Product program	Product focus	Target market*	Potential expansion**
Bio-Stimulants
	Seed treatment, Spring wheat North America	25M ACRES wheat North America	500M ACRES
LAV228 Bio-stimulants 2	Seed treatment Soy N.A, Europe	85M ACRES soy US	180M ACRES
Bio-stimulants 3	Foliar treatment Soy Brazil, US & LATAM	100M ACRES soy Brazil	140M ACRES
Bio-stimulants 4	Foliar treatment Cotton Brazil, US, India	40M ACRES cotton Brazil, US, & India	90M ACRES
Bio-Pesticides
Fruit rots	Foliar treatment Fruits & Veg Europe. N.A	<\$200M grapes chemicals usage	+\$800M Additional Fruits & Veg
LAV321 Downey mildew	Foliar treatment Fruits & Veg Europe. N.A	<\$350M grapes chemicals usage	+\$150M Additional Fruits & Veg
LAV332 Seedling disease (Pythium)	Seed treatment, Corn, soy, F&V Europe, N.A	<\$500M	<\$200M
LAV441, LAV442 Bio-Insecticides	Seed treatment, Corn, soy Europe, N.A	<\$1.5B existing traits and chemicals market	<\$500M

* Company estimations for the target market of initial crops and disease based on FAO, OECD & USDA data ** Company estimations for total addressable market including potential geographies & crop expansions

Confidential

Product Example A bio-control product for vineyards (fruit rot)

Consistent performance in preventative application over 3 years (validated by Corteva)
Superior performance compared to competing biological control products, similar results to chemicals
Integrated spray programs showed potential reduction of 3-5 chemical applications* per season
Potential annual product sales >\$100m**

Product Example

A bio-control for vineyards & vegetables (Downey Mildew & Late Blight)

Field proven against Downy Mildew (grapes) & Late Blight (potato & tomato)
2 years testing by 4 multinationals with consistent performance & strong results
Limited solutions in the market due to pest resistance and regulatory constraints
Potential annual product sales >\$100m*

Single Product Market Potential

From focused development to large market potential

Business Model

Lavie Bio product

End-to-end product development
Production by contractor
Commercialization via direct channels
Revenues from sales

Lavie Bio 'tech-inside' product

End-to-end product development
Licensing by industry leader
Commercialization & production by partner
Revenues from upfront payment, milestones & royalties

Direct Model

G2M Step 1

Bottom-up demand generation and sales through regional distribution partners

Current Thrivus US distribution partners

G2M Step 2

Scale-up through national partners

Potential US national partners

Licensing Model

Corteva to license Lavie Bio's bio-fungicide LAV311 & LAV312 for fruit rot

• Global exclusive license upon reaching diligence milestones

• Deal terms:

• Deal includes LAV311 as main strain and LAV312 as a back-up

Strategic Investors & Partners

Global leader in computational biology

• Strategic Investor: Evogene holdings – 70%

• Strategic partner:

Exclusive long-term license for MicroBoost AI technology for agriculture

Global leader in seeds and ag-chemical products

Strategic Investor: Corteva holdings – 28% \$27M investment (Aug 2019)*
Strategic partner: 2 joint bio-pesticide development programs

Global leader in fertilizers and specialty minerals

• Strategic Investor: \$10M SAFE investment (Aug 2022)

• Strategic partner: 2 joint bio-stimulant development programs

We've got the right team to nurture it

Management Team

Amit Noam

| CEO

An extensive experience in the agriculture and healthcare sectors, leading teams in the development and execution of commercialization strategies, driving long-term growth and value-creation for businesses

Michael Ionesco

| VP Research

Innovative research leader with deep biotechnology, big data and informatics expertise

Board of Directors

Ofer Haviv

Chairman of the board Evogene's President and CEO

Sassi Masliah

Vice President Corporate Development at Evogene

Dor Kestecher

| VP Business Development

10+ years of broad experience leading in agriculture product management, strategy, and development

Russel Putland

| EVP Commercial and US General Manager

30+ years of ag commercial leadership roles with 'ground up' experience in large multi-national organizations

Yaron Eldad CFO

Over 25 years of experience in various CFO positions in public and private technology and biotechnology companies,

Amir Bercovitz

Frederic C. Beudot Global Portfolio Leader for

Biologicals at Corteva Agriscience

| VP Development Extensive development and

product expertise in the agbiologicals field for 30+ years – led introductions of 5 commercial products

Elad Aharonson

President, Growing Solutions at ICL

Senior agriculture executive, experienced in marketing, sales, and go-to-market

Summary

A

Ag-biologicals - a \$10B market, forecasted to grow at a 13% CAGR over the next decade

B

Unique tech edge – enables to systematically bring sustainable agbiological products to the market, with comparable efficiency to synthetic solutions

D

Proven end-to-end product development capabilities with 2 graduated programs generating revenues: Thrivus (direct model) & LAV311 (licensing model)

E

Strong market acknowledgement - Corteva, ICL & Evogene as strategic investors & partners

C

Broad & diverse pipeline of 8 bio-stimulant and bio-pesticide products targeting a new product launch every 1-2 years